Decoy Therapeutics Reports Promising Ebola Activity for Broad-Spectrum Antiviral Candidate
Decoy Therapeutics Inc, a biotechnology company focused on developing Designable Multi-Antivirals (D-MAVs), has announced that one of its D-MAV candidates has demonstrated in vitro effectiveness against the wild-type Ebola Zaire virus during testing conducted at the Texas Biomedical Research Institute. Encouraged by these findings, the company has launched an exploratory research initiative to create D-MAV therapies targeting filoviruses, including Ebola and Marburg viruses.
The D-MAV candidate was originally developed using Decoy's IMP3ACT platform to prevent coronavirus entry into host cells, where it has already exhibited nanomolar to picomolar potency against a broad range of known coronavirus variants. Its newly observed activity against Ebola Zaire—a filovirus responsible for 17 of the last 20 Ebola outbreaks—supports the company's approach of designing a single antiviral capable of targeting shared viral mechanisms across multiple virus families.
"Our industry has traditionally taken a reactive, one-virus-at-a-time approach, leaving us continually responding to emerging viral threats," said Rick Pierce, Chief Executive Officer of Decoy Therapeutics.
"While advancing our respiratory disease program toward clinical development remains our primary focus, these findings expand our confidence in the broader capabilities of our platform."
The same laboratory studies also found that the candidate exhibited in vitro activity against the Lassa fever virus, an arenavirus. Diseases caused by filoviruses and arenaviruses—including Ebola, Marburg, and Lassa fever—qualify for the U.S. Food and Drug Administration's Tropical Disease Priority Review Voucher program, which is intended to encourage the development of treatments for neglected infectious diseases.
Dr. Barbara Hibner, Chief Scientific Officer and Co-Founder of Decoy Therapeutics, explained that the D-MAV was designed to target a viral entry mechanism relied upon by coronaviruses, yet it also inhibited filovirus infection because these viruses use the same class I fusion machinery. She noted that the results validate the company's broad-spectrum antiviral strategy and highlight the versatility of the D-MAV platform. The company is now working on new D-MAV candidates aimed at simultaneously targeting filoviruses and arenaviruses, with the expectation that its platform can speed their development.
According to Decoy Therapeutics, the ability to address both commercial infectious diseases and pandemic preparedness through a unified technology platform is central to its strategy. The latest findings reinforce that vision, particularly as ongoing Ebola outbreaks in the Democratic Republic of the Congo and Uganda—caused by the Bundibugyo virus and currently lacking approved vaccines or treatments—continue to emphasize the need for broad-spectrum antiviral solutions.
The D-MAV candidate was originally developed using Decoy's IMP3ACT platform to prevent coronavirus entry into host cells, where it has already exhibited nanomolar to picomolar potency against a broad range of known coronavirus variants. Its newly observed activity against Ebola Zaire—a filovirus responsible for 17 of the last 20 Ebola outbreaks—supports the company's approach of designing a single antiviral capable of targeting shared viral mechanisms across multiple virus families.
"Our industry has traditionally taken a reactive, one-virus-at-a-time approach, leaving us continually responding to emerging viral threats," said Rick Pierce, Chief Executive Officer of Decoy Therapeutics.
"While advancing our respiratory disease program toward clinical development remains our primary focus, these findings expand our confidence in the broader capabilities of our platform."
The same laboratory studies also found that the candidate exhibited in vitro activity against the Lassa fever virus, an arenavirus. Diseases caused by filoviruses and arenaviruses—including Ebola, Marburg, and Lassa fever—qualify for the U.S. Food and Drug Administration's Tropical Disease Priority Review Voucher program, which is intended to encourage the development of treatments for neglected infectious diseases.
Dr. Barbara Hibner, Chief Scientific Officer and Co-Founder of Decoy Therapeutics, explained that the D-MAV was designed to target a viral entry mechanism relied upon by coronaviruses, yet it also inhibited filovirus infection because these viruses use the same class I fusion machinery. She noted that the results validate the company's broad-spectrum antiviral strategy and highlight the versatility of the D-MAV platform. The company is now working on new D-MAV candidates aimed at simultaneously targeting filoviruses and arenaviruses, with the expectation that its platform can speed their development.
According to Decoy Therapeutics, the ability to address both commercial infectious diseases and pandemic preparedness through a unified technology platform is central to its strategy. The latest findings reinforce that vision, particularly as ongoing Ebola outbreaks in the Democratic Republic of the Congo and Uganda—caused by the Bundibugyo virus and currently lacking approved vaccines or treatments—continue to emphasize the need for broad-spectrum antiviral solutions.
Companies